IF
ALDX icon

Ironwood Financial’s Aldeyra Therapeutics ALDX Stock Holding History

Ironwood Financial’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-500
Closed -$4K – 365
2015
Q2 		$4K Hold
500
– – ﹤0.01% 263
2015
Q1 		$5K Buy
+500
New +$5.1K ﹤0.01% 244

Other funds holding ALDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Ironwood Financial's ALDX Position: Q3 2015 in Review

Ironwood Financial sold out of Aldeyra Therapeutics (ALDX) in Q3 2015, closing a stake of 500 shares — an estimated $4K sold.

Ironwood Financial first reported a position in ALDX in Q1 2015 and held it in 2 quarters. The position peaked at $5K in Q1 2015. 22 funds tracked by Wall St. Rank hold ALDX as of Q3 2015.

  • Ironwood Financial reported no remaining Aldeyra Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Ironwood Financial sold 500 Aldeyra Therapeutics shares in Q3 2015, an estimated $4K.
  • Ironwood Financial first reported a position in Aldeyra Therapeutics in Q1 2015 and held it in 2 quarters.
  • Ironwood Financial's Aldeyra Therapeutics position peaked at $5K in Q1 2015.
  • 22 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2015.

Based on Ironwood Financial's 13F filing for Q3 2015, filed 9 Nov 2015.